- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04818970
Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients
Adaptive Photo-Protection Trial: To Demonstrate the Safety and Efficacy of NB-UVB Light Therapy to Improve Outcomes in Hospitalized High-risk Patients With COVID-19
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Design
This is a multi-center, double blind, randomized control trial designed to assess the safety and efficacy of daily NB-UVB light for patients presenting to site hospitals over the age of 50 with a positive COVID-19 panel and at least one comorbidity.
This trial provides adjunctive therapy and no in-hospital treatments need to be modified in any way. The sponsor and the centers acknowledge standards of care are actively evolving and this trial is not intended to interfere in any form.
Double Blind: Patient and Health care provider will be blinded to the treatment vs. placebo by use of a non-NB-UVB light card. All dosing and times for treatment and placebo will be calculated the same methods.
Arm A: Control: Will receive non-NB-UVB light during the Treatment Period.
Arm B: Treatment: Will receive NB-UVB light during the Treatment Period.
Treatment Phase (Days 1-8): Treatment Schedule will be identical for arm A and B.
Follow Up Phase (Days 9-28 or discharge): Follow-up will be identical for arms A and B.
Blood Draw Schedule: Blood draws are to be performed after enrollment, before the first treatment day 1 and on days 3, 5, 8, 14 and day of discharge (if prior to day 14 unless blood draw has already occurred within one day of discharge).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- West Jefferson Medical Center and LSUHSC-NO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
To be eligible to enroll in the study, subjects must be:
- In-Hospital
- 50 years of age or older
- Hospitalized for COVID-I9 symptoms
- At least one comorbidity.
- They have taken a COVID-19 diagnostic test.
- Peripheral 02 saturation below 94 on room air, nasal cannula or non-rebreather
- Patients may remain enrolled as long as they remain hospitalized for
- COVID-19 symptoms and receive a positive test panel for COVID-19
- during the treatment phase
- Be able to provide consent.
Exclusion Criteria:
-
To be eligible to enroll in the study, subjects must not:
- Require ventilatory support at the time of enrollment.
- Concurrent pulmonary bacterial infection
- Taking Light Sensitive Medications
- Have Lupus Diagnosis
- Enrolled in an existing Covid-19 Trial
- Taking In-patient Vitamin oral Supplementation
- Severe mental or medical disability
- History of melanoma or dysplastic nevus syndrome
- Prisoner
- Active tuberculosis or Cystic Fibrosis, Severe Chronic Obstructive Pulmonary Disease (COPD) or Pulmonary Fibrosis requiring home supplemental oxygen
- Pre-existing pulmonary hypertension
- INR > 2, LFT 6 times greater than baseline
- Stage 3b CKD or ESRD diagnosis before COVID-19 onset
- Evidence of cirrhosis
- Evidence of pre-existing vascular disorder or coagulopathy
- Irreversible bleeding disorder
- Patients who are not full code
- Taking oral light sensitizing medications (See Appendix) or using light sensitizing topical
- medication in the phototherapy treatment zones
- Taking in patient or at home Vitamin D supplementation
- Have any photosensitive skin disorder such as Systemic Lupus Erythematosus, Porphyria or
- Pseudoporphyria, Polymorphous Light Eruption Xeroderma Pigmentosa, Chronic actinic
- dermatitis, Hydroa vacciniforme, Dermatomyositis Bloom Syndrome, Rothmund Thomas
- syndrome, Cockayne Syndrome
- Requiring oxygen supplementation via CPAP/BiPAP, ventilator support, High Flow Nasal
- Prong therapy (HFNP)
- Concurrent pulmonary bacterial infection at the time of enrollment
- Previous hospital admission for COVID-19 symptoms
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phototherapy of narrow band ultraviolet Light B-Band NB-UVB
Daavlin Series 1 Phototherapy Unit that emits UVB light between 280nm and 320nm.
|
Daily doses of NB-UVB for 8 consecutive days.
Other Names:
|
Placebo Comparator: Placebo - Light
Daavlin Series 1 Phototherapy Unit that does not emit UVB light between 280nm and 320 nm.
|
Daily doses of non-NB-UVB for 8 consecutive days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality Rate
Time Frame: 14 days
|
% Patient Mortality
|
14 days
|
Mortality Rate
Time Frame: 28 days
|
% Patient Mortality
|
28 days
|
WHO Ordinal Scale for Clinical Improvement
Time Frame: 14 days
|
Improvement in WHO Ordinal Scale
|
14 days
|
WHO Ordinal Scale for Clinical Improvement
Time Frame: 28 days
|
Improvement in WHO Ordinal Scale
|
28 days
|
Length of Hospital Stay
Time Frame: 28 days
|
Days from Treatment to Discharge
|
28 days
|
Rate of Escalation to the ICU
Time Frame: day 14
|
% of Patients Escalating to the ICU
|
day 14
|
Rate of Ventilator Support (intubation) requirement
Time Frame: day 28
|
% of Patients Requiring Ventilator Support (intubation)
|
day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Improved Immune Regulation as measured by (Any 3 of These):
Time Frame: 28 days
|
|
28 days
|
Rate of Stabilization of the Immune Dysregulation (all 3 of These)
Time Frame: 28 days
|
|
28 days
|
Average Reduction in Inflammatory Markers:
Time Frame: 28 days
|
HS-CRP (mg/L)
|
28 days
|
Average Reduction in Inflammatory Markers:
Time Frame: 28 days
|
LDH (units per liter (U/L))
|
28 days
|
Average Reduction in Inflammatory Markers:
Time Frame: 28 days
|
Ferritin (micrograms/L)
|
28 days
|
Improved Hemostatic Regulation by D-dimer Reduction
Time Frame: 28 days
|
D-dimer (ng/mL)
|
28 days
|
Improved Hemostatic Regulation by reduce PTT
Time Frame: 28 days
|
Partial Thromboplastin Time (PTT) Test
|
28 days
|
Average Reduced Viral Load.
Time Frame: 28 days
|
Reduced viral load (copies/mL)
|
28 days
|
Average and Categorical Increase in Vitamin D:
Time Frame: 28 days
|
i. % of Patients with Improvement from Insufficient (at min. of 18pg/ml); |
28 days
|
% of Patients with a Change in oxygen requirement
Time Frame: 28 days
|
|
28 days
|
Average Temperature
Time Frame: 28 days
|
|
28 days
|
Average Length of Hospitalization
Time Frame: 28 days
|
Days in the ICU Days to Discharge Need for Rehospitalization Need for COVID Related Rehospitalization
|
28 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Frank H Lau, MD, Louisiana State University Health Sciences Center in New Orleans
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- COVID-19
- Coronavirus Infections
- Hemostatic Disorders
- Blood Coagulation Disorders
- Autoimmune Diseases
Other Study ID Numbers
- TPL0001-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autoimmune Diseases
-
SanofiCompletedHealthy Volunteers | Autoimmune DisorderUnited States
-
National Eye Institute (NEI)Completed
-
The Eye Center and The Eye Foundation for Research...CompletedAutoimmune Polyglandular Syndrome Type I | Autoimmune Keratitis
-
Sinocelltech Ltd.Not yet recruiting
-
TakedaCompletedAutoimmune DiseaseUnited Kingdom
-
Ziv HospitalUnknownAutoimmune DiseaseIsrael
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedAutoimmune DisordersUnited States
-
Muğla Sıtkı Koçman UniversityCompletedMultiple Sclerosis | Telerehabilitation | Autoimmune Disorder | Exercise ProgramTurkey
-
Fundación Pública Andaluza Progreso y SaludKarolinska Institutet; Eli Lilly and Company; Medical University of Vienna; Sanofi and other collaboratorsCompletedSystemic Autoimmune DiseasesFrance, Belgium, Germany, Italy, Spain, Switzerland
-
Ruijin HospitalRecruiting
Clinical Trials on Narrow Band ultraviolet B-Band Light
-
Cairo UniversityCompletedActive Non Segmental VitiligoEgypt
-
Johns Hopkins UniversityTerminatedVitiligo | Pigmentation | DyschromiaUnited States
-
Mercy Medical CenterAdvocate Lutheran General Hospital; Olympus America, Inc.CompletedEndometriosisUnited States
-
South Valley UniversityCompleted
-
Clinical Research Office of the Endourological...Completed
-
Incyte CorporationCompletedVitiligoUnited States, Canada
-
National Institute of Allergy and Infectious Diseases...PPD; Amgen; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)Active, not recruiting
-
Assiut UniversityUnknown
-
Changi General HospitalCompletedGastric Cancer | Gastric Intestinal MetaplasiaSingapore
-
The Catholic University of KoreaUnknownVitiligo | Phototherapy | Maintenance Therapy | Narrow-band UV-BKorea, Republic of